Physician profile
Chintan Patel
NPI 1710240395
$31,438.57
in general payments reported to CMS, 2019-2025
30 companies · $4,677 in 2025
The $4,677 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,120 · 2020: $611 · 2021: $316 · 2022: $886 · 2023: $9,801 · 2024: $11K · 2025: $4,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Food and Beverage: $2,997 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $550 · Travel and Lodging: $325 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,600.00 |
| Food and Beverage | $2,996.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $550.00 |
| Travel and Lodging | $324.76 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microline Surgical INC | $21,600.00 | 2023-2025 | |
| Genzyme Corporation | $2,730.08 | 2019 | |
| Axonics, INC. | $1,075.16 | 2021-2024 | Axonics, Bulkamid |
| Teleflex LLC | $1,028.41 | 2022-2024 | Urolift |
| Procept Biorobotics Corporation | $837.13 | 2022-2025 | |
| Coloplast Corp | $767.93 | 2019-2025 | |
| Boston Scientific Corporation | $583.41 | 2019-2025 | Axonics, Lithovue, Rezum Generator |
| Gyrus Acmi, INC. | $550.00 | 2023 | |
| Neotract INC. | $439.79 | 2019-2020 | |
| Astellas Pharma US INC | $318.08 | 2019-2024 | Xtandi, Myrbetriq |
| Koelis INC. | $181.67 | 2020-2021 | |
| Progenics Pharmaceuticals, INC. | $151.33 | 2022-2024 | |
| Avadel Specialty Pharmaceuticals, LLC | $147.46 | 2019 | |
| Dornier Medtech America, INC | $127.25 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $118.82 | 2020-2025 | Lynparza, Imfinzi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $107.60 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Abbvie INC. | $97.11 | 2022-2023 | |
| Endo Pharmaceuticals INC. | $83.01 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $76.67 | 2025 | |
| Photocure INC | $66.49 | 2023 | Cysview |
| Merck Sharp & Dohme LLC | $66.31 | 2020-2022 | |
| Calyxo, INC. | $46.42 | 2025 | Cvac Aspiration System |
| Bayer Healthcare Pharmaceuticals INC. | $44.98 | 2022 | |
| Astellas Pharma Global Development | $37.47 | 2024 | Xtandi |
| Pfizer INC. | $35.57 | 2021-2024 | |
| Urogen Pharma, INC. | $25.45 | 2023 | Jelmyto |
| Antares Pharma, INC. | $24.99 | 2022 | |
| Telix Pharmaceuticals | $24.98 | 2025 | Illuccix |
| Myovant Sciences INC. | $24.18 | 2021 | |
| Tolmar, INC. | $20.82 | 2025 | Jatenzo, Eligard |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chintan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.